Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIVEX study of SIR9900 in VEXAS syndrome
CTR20261190Phase 2Active
- Sponsor
- Vitality Biopharma, Inc.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SIR9900 in VEXAS syndrome (VEXAS), sponsored by Vitality Biopharma, Inc.. Started May 2026; status: active.
02
Drugs
SIR9900
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on CTR20261190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261190.